TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
This is a single center double-blind placebo-controlled study. Patients with GPA and active ears, nose, and throat (ENT) disease in at least two ENT domains, as defined after endoscopic visualization of the upper airway and audiometric evaluation, if applicable, by a single otolaryngologist using a validated GPA ENT disease activity score, will be eligible for inclusion. Patients will be treated with standard of care (SOC) treatment as determined by their treating rheumatologist. In addition to SOC, patients will be randomized to receive TAVNEOS 30mg BID or placebo. Patients will be followed for 52 weeks with standardized ENT assessment along with rheumatologic evaluation of overall disease activity with BVAS.
GPA diagnosis defined by score of ≥5 on 2022 ACR/EULAR Classification Criteria f... [+12]
Creatinine >4.0mg/dl or GFR <15 at baseline or dependence on dialysis [+21]